La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Dr. Sulaiman Al Habib Medical Services Group Croissance future
Future contrôle des critères 4/6
Dr. Sulaiman Al Habib Medical Services Group devrait augmenter ses bénéfices et son chiffre d'affaires de 14.6% et de 14.1% par an respectivement. Le BPA devrait croître de de 14.1% par an. Le rendement des capitaux propres devrait être 39.1% dans 3 ans.
Informations clés
14.9%
Taux de croissance des bénéfices
14.6%
Taux de croissance du BPA
Healthcare croissance des bénéfices | 14.8% |
Taux de croissance des recettes | 14.7% |
Rendement futur des capitaux propres | 39.1% |
Couverture par les analystes | Good |
Dernière mise à jour | 13 Sep 2024 |
Mises à jour récentes de la croissance future
Dr. Sulaiman Al Habib Medical Services Group Company (TADAWUL:4013) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
May 03Earnings Beat: Dr. Sulaiman Al Habib Medical Services Group Company Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Apr 27Recent updates
Investors Will Want Dr. Sulaiman Al Habib Medical Services Group's (TADAWUL:4013) Growth In ROCE To Persist
Jul 04Dr. Sulaiman Al Habib Medical Services Group's (TADAWUL:4013) Shareholders Will Receive A Bigger Dividend Than Last Year
May 23Dr. Sulaiman Al Habib Medical Services Group (TADAWUL:4013) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
May 08Dr. Sulaiman Al Habib Medical Services Group Company (TADAWUL:4013) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
May 03Subdued Growth No Barrier To Dr. Sulaiman Al Habib Medical Services Group Company's (TADAWUL:4013) Price
Apr 29There's Been No Shortage Of Growth Recently For Dr. Sulaiman Al Habib Medical Services Group's (TADAWUL:4013) Returns On Capital
Mar 15Dr. Sulaiman Al Habib Medical Services Group's (TADAWUL:4013) Dividend Will Be SAR1.15
Feb 22With EPS Growth And More, Dr. Sulaiman Al Habib Medical Services Group (TADAWUL:4013) Makes An Interesting Case
Feb 20Dr. Sulaiman Al Habib Medical Services Group Company's (TADAWUL:4013) Price Is Out Of Tune With Earnings
Jan 09We Like These Underlying Return On Capital Trends At Dr. Sulaiman Al Habib Medical Services Group (TADAWUL:4013)
Nov 28We Think That There Are Issues Underlying Dr. Sulaiman Al Habib Medical Services Group's (TADAWUL:4013) Earnings
Nov 07Dr. Sulaiman Al Habib Medical Services Group's (TADAWUL:4013) Shareholders Will Receive A Bigger Dividend Than Last Year
Nov 02Here's Why Dr. Sulaiman Al Habib Medical Services Group (TADAWUL:4013) Has Caught The Eye Of Investors
Sep 21Dr. Sulaiman Al Habib Medical Services Group (TADAWUL:4013) Is Doing The Right Things To Multiply Its Share Price
Aug 10Here's Why We Think Dr. Sulaiman Al Habib Medical Services Group (TADAWUL:4013) Is Well Worth Watching
Jun 17Dr. Sulaiman Al Habib Medical Services Group's (TADAWUL:4013) Shareholders Will Receive A Bigger Dividend Than Last Year
May 12Returns At Dr. Sulaiman Al Habib Medical Services Group (TADAWUL:4013) Are On The Way Up
May 06Here's Why We Think Dr. Sulaiman Al Habib Medical Services Group (TADAWUL:4013) Might Deserve Your Attention Today
Mar 13Dr. Sulaiman Al Habib Medical Services Group's (TADAWUL:4013) Returns On Capital Are Heading Higher
Jan 30With EPS Growth And More, Dr. Sulaiman Al Habib Medical Services Group (TADAWUL:4013) Makes An Interesting Case
Dec 07Dr. Sulaiman Al Habib Medical Services Group (TADAWUL:4013) Is Doing The Right Things To Multiply Its Share Price
Oct 23If EPS Growth Is Important To You, Dr. Sulaiman Al Habib Medical Services Group (TADAWUL:4013) Presents An Opportunity
Sep 08Estimating The Intrinsic Value Of Dr. Sulaiman Al Habib Medical Services Group Company (TADAWUL:4013)
Aug 24Why Dr. Sulaiman Al Habib Medical Services Group Company (TADAWUL:4013) Could Be Worth Watching
Aug 08Dr. Sulaiman Al Habib Medical Services Group (TADAWUL:4013) Has More To Do To Multiply In Value Going Forward
Jul 12Does Dr. Sulaiman Al Habib Medical Services Group (TADAWUL:4013) Deserve A Spot On Your Watchlist?
May 31A Look At The Fair Value Of Dr. Sulaiman Al Habib Medical Services Group Company (TADAWUL:4013)
May 17Dr. Sulaiman Al Habib Medical Services Group (TADAWUL:4013) Will Pay A Larger Dividend Than Last Year At ر.س0.83
Apr 28Should You Think About Buying Dr. Sulaiman Al Habib Medical Services Group Company (TADAWUL:4013) Now?
Apr 09Return Trends At Dr. Sulaiman Al Habib Medical Services Group (TADAWUL:4013) Aren't Appealing
Mar 06Here's Why I Think Dr. Sulaiman Al Habib Medical Services Group (TADAWUL:4013) Is An Interesting Stock
Feb 16Returns On Capital At Dr. Sulaiman Al Habib Medical Services Group (TADAWUL:4013) Have Stalled
Dec 05Do Dr. Sulaiman Al Habib Medical Services Group's (TADAWUL:4013) Earnings Warrant Your Attention?
Nov 17Investors Could Be Concerned With Dr. Sulaiman Al Habib Medical Services Group's (TADAWUL:4013) Returns On Capital
Aug 30Here's Why I Think Dr. Sulaiman Al Habib Medical Services Group (TADAWUL:4013) Might Deserve Your Attention Today
Aug 01Estimating The Fair Value Of Dr. Sulaiman Al Habib Medical Services Group Company (TADAWUL:4013)
Jun 11Capital Allocation Trends At Dr. Sulaiman Al Habib Medical Services Group (TADAWUL:4013) Aren't Ideal
May 27Earnings Beat: Dr. Sulaiman Al Habib Medical Services Group Company Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Apr 27Here's Why I Think Dr. Sulaiman Al Habib Medical Services Group (TADAWUL:4013) Might Deserve Your Attention Today
Apr 06A Look At The Fair Value Of Dr. Sulaiman Al Habib Medical Services Group Company (TADAWUL:4013)
Feb 04Is Dr. Sulaiman Al Habib Medical Services Group Company's (TADAWUL:4013) Shareholder Ownership Skewed Towards Insiders?
Jan 14Dr. Sulaiman Al Habib Medical Services Group Company (TADAWUL:4013) Is Yielding 1.5% - But Is It A Buy?
Dec 23Dr. Sulaiman Al Habib Medical Services Group Company's (TADAWUL:4013) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?
Nov 27Prévisions de croissance des bénéfices et des revenus
Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
---|---|---|---|---|---|
12/31/2026 | 15,646 | 3,235 | 2,325 | 4,260 | 9 |
12/31/2025 | 13,356 | 2,676 | 1,407 | 3,564 | 9 |
12/31/2024 | 10,967 | 2,232 | -278 | 3,049 | 6 |
6/30/2024 | 10,024 | 2,176 | -1,046 | 3,031 | N/A |
3/31/2024 | 9,723 | 2,108 | -758 | 3,291 | N/A |
12/31/2023 | 9,508 | 2,046 | -253 | 3,244 | N/A |
9/30/2023 | 9,276 | 1,962 | 60 | 3,072 | N/A |
6/30/2023 | 8,885 | 1,838 | 509 | 2,789 | N/A |
3/31/2023 | 8,627 | 1,750 | 1,219 | 2,932 | N/A |
12/31/2022 | 8,311 | 1,651 | 1,330 | 2,844 | N/A |
9/30/2022 | 8,025 | 1,593 | 838 | 2,411 | N/A |
6/30/2022 | 7,809 | 1,521 | 956 | 2,254 | N/A |
3/31/2022 | 7,547 | 1,448 | 1,067 | 2,419 | N/A |
12/31/2021 | 7,250 | 1,377 | 929 | 2,183 | N/A |
9/30/2021 | 6,974 | 1,311 | 1,156 | 2,441 | N/A |
6/30/2021 | 6,761 | 1,261 | 1,120 | 2,170 | N/A |
3/31/2021 | 6,213 | 1,128 | 1,219 | 2,183 | N/A |
12/31/2020 | 5,862 | 1,055 | 1,420 | 2,234 | N/A |
9/30/2020 | 5,575 | 1,008 | 1,219 | 1,871 | N/A |
6/30/2020 | 5,178 | 907 | 1,030 | 1,743 | N/A |
3/31/2020 | 5,132 | 883 | 503 | 1,155 | N/A |
12/31/2019 | 5,016 | 870 | 326 | 1,059 | N/A |
9/30/2019 | 4,816 | 825 | 843 | 1,549 | N/A |
6/30/2019 | 4,735 | 835 | 753 | 1,539 | N/A |
3/31/2019 | 4,646 | 819 | 1,005 | 1,760 | N/A |
12/31/2018 | 4,588 | 801 | 789 | 1,447 | N/A |
12/31/2017 | 4,687 | 658 | N/A | 1,058 | N/A |
12/31/2016 | 4,868 | 1,010 | N/A | 900 | N/A |
12/31/2015 | 5,123 | 1,329 | N/A | 922 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de 4013 ( 14.6% par an) est supérieure au taux d'épargne ( 14.5% ).
Bénéfices vs marché: Les bénéfices de 4013 ( 14.6% par an) devraient croître plus rapidement que le marché SA ( 6.7% par an).
Croissance élevée des bénéfices: Les bénéfices de 4013 devraient augmenter, mais pas de manière significative.
Chiffre d'affaires vs marché: Le chiffre d'affaires de 4013 ( 14.1% par an) devrait croître plus rapidement que le marché SA ( 0.9% par an).
Croissance élevée des revenus: Le chiffre d'affaires de 4013 ( 14.1% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Le retour sur capitaux propres de 4013 devrait être élevé dans 3 ans ( 39.1 %)